following information must be provided:

A. A copy of the face page of the application (SF 424).

B. A summary of the project that should be titled ''Public Health System Impact Statement'' (PHSIS), not to exceed one page, and include the following:

1. A description of the population to be served;

2. A summary of the services to be provided; and

3. A description of the coordination plans with the appropriate State and/or local health agencies.

If the State and/or local health official should desire a copy of the entire application, it may be obtained from the State Single Point of Contact (SPOC) or directly from the applicant.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance number is 93.268.

Other Requirements

Human Subjects

If the proposed project involves research on human subjects, the applicant must comply with the Department of Health and Human Services Regulations, 45 CFR Part 46, regarding the protection of human subjects. Assurance must be provided to demonstrate that the project will be subject to initial and continuing review by an appropriate institutional review committee. The applicant will be responsible for providing assurance in accordance with the appropriate guidelines and forms provided in the application kit.

Application Submission and Deadline

A. Preapplication Letter of Intent

Although not a prerequisite of application, a non-binding letter of intent-to-apply is requested from potential applicants. The letter should be submitted to the Grants Management Specialist (whose address is reflected in section B, ''Applications''). It should be postmarked no later than one month prior to the planned submission deadline, (e.g., June 12 for a July 12 submission). The letter should identify the announcement number, the name of the applicant AMC or CHN and its Project Collaborators, as defined in this announcement, and the geographic type (urban or rural) of program which the intended application will address. The letter of intent does not influence review or funding decisions, but it will enable CDC to plan the review more efficiently and thereby potentially benefit all applicants.

B. Application

The application should be carefully completed, following the directions provided in this program announcement. The original and two copies of the application PHS Form 5161–1 must be submitted to Lisa G. Tamaroff, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, Room 300, Mailstop E–13, Atlanta, Georgia 30305, on or before July 12, 1996.

1. Deadline

Applications will be considered as meeting the deadline if they are either:

a. Received on or before the deadline date; or

b. Sent on or before the deadline date and received in time for submission to the triage process, if it is employed, or the objective review process if it is not. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

2. Late Applications

Applications that do not meet the criteria in 1.a. or 1.b. above are considered late applications. Late applications will not be considered and will be returned to the applicant.

Where To Obtain Additional Information

To receive additional written information call (404) 332–4561. You will be asked to leave your name, address, and phone number and will need to refer to Announcement #612. You will receive a complete program description. The program announcement is also available on through the CDC homepage on the Internet. The address for the CDC homepage is http://www.cdc.gov. CDC will not send program announcements by facsimile or express mail. If you have any questions after reviewing the contents of all the documents, business management technical assistance may be obtained from Lisa Tamaroff, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, Mailstop E–13, Atlanta, Georgia 30305, telephone (404) 842–6796, Internet address: lgt1@opspgo1.em.cdc.gov.

Programmatic technical assistance may be obtained from Russ Havlak, Immunization Services Division, National Immunization Program, Centers for Disease Control and Prevention (CDC), Building 12, Corporate Square Boulevard, Mailstop E–52, Atlanta, Georgia 30329, telephone (404) 639–8569, Internet address: grh1@cpstb1.em.cdc.gov.

Please refer to Announcement Number 612 when requesting information and submitting an application.

There may be delays in mail delivery as well as difficulty in reaching the CDC Atlanta offices during the 1996 Summer Olympics (July 19–August 4). Therefore, CDC suggests the following to get more timely responses to any questions: using internet/email, following all instructions in this announcement, and leaving messages on the contact person's voice mail.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017–001–00474–0) or Healthy People 2000 (Summary Report, Stock No. 017–001–00473–1) referenced in the Introduction through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402–9325, telephone: 202–512–1800.

Dated: May 2, 1996.

Joseph R. Carter,

Acting Associate Director for Management and Operations Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–11443 Filed 5–7–96; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates,

can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Veterinary Medicine Advisory Committee

Date, time, and place. May 29, 1996, 8:30 a.m., Holiday Inn—Gaithersburg, Goshen Room, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, 8:30 a.m. to 10:30 a.m.; open public hearing, 10:30 a.m. to 11:30 a.m., unless public participation does not last that long; open committee discussion, 11:30 a.m. to 2:30 p.m.; open public hearing, 2:30 p.m. to 3:30 p.m., unless public participation does not last that long; Joanne M. Kla, Center for Veterinary Medicine (HFV–244), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1765, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Veterinary Medicine Advisory Committee, code 12546. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates available data concerning safety and effectiveness of marketed and investigational new animal drugs, feeds, and devices for use in the treatment and prevention of animal disease and increased animal production.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentation should notify the contact person before May 22, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. FDA relies on States and the milk industry for much of the routine drug residue monitoring, and in conjunction with the National Conference on Interstate Milk Shipments (NCIMS), uses its limited resources in the training of a wide range of State and industry personnel, provides testing for the accreditation of State laboratories, and conducts a limited number of assays. The General Accounting Office (GAO) recently recommended that FDA develop a comprehensive strategy to address animal drug residues in milk. The first topic to be addressed by the committee will be a draft document entitled ''FDA Strategy To Address Animal Drug Residues In Milk.'' During the afternoon, the committee will discuss the status of the sometribove Post-Approval Monitoring Program (PAMP). FDA approved sometribove, a recombinant bovine somatotropin (bST) on November 12, 1993 (58 FR 55946), and the product, Posilac®, began commercial distribution on February 4, 1994. Steps have been taken to monitor sometribove in commercial use. The Monsanto Co. is conducting a PAMP that includes the following elements:

- A study of animal health effects including mastitis, animal drug use and resulting loss of milk associated with bST use in a minimum of 24 commercial dairy herds. The in-life portion of this study were recently completed. The committee will hear a brief status report on May 29, 1996, and will consider the report in detail during the fall of 1996 after the quality assurance and statistical treatments of the data are complete.
- A 2-year tracking system of milk production and drug residues in key dairy States that represent over 50 percent of the total U.S. milk production to compare the amount of milk discarded due to drug residues before and after bST approval.
- A 12-month comparison of the proportion of milk discarded due to possible drug residues between bST treated and untreated herds.
- A reporting system to monitor bST use and reports of adverse drug experiences. The committee will also consider the 2-year tracking system to compare mild discarded pre- versus post-bST approval and adverse experience reports filed with FDA during the first 2 years of sometribove commercial use.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday

through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: April 29, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–11436 Filed 5–7–96; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

[HCFA–319]

Agency Information Collection Activities: Proposed Collection: Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposals for the collection of information. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Request:* Reinstatement, without change, of a previously approved collection for which approval has expired; *Title of Information Collection:* State Medicaid Eligibility Quality Control (MEQC) Sample Selection Lists; *Form No.:* HCFA–319; *Use:* The State MEQC sample selection list is necessary for regional offices to control and track State MEQC reviews. The sample selection lists contain identifying information on Medicaid beneficiaries; *Frequency:* Monthly; *Affected Public:* State, local, or tribal government; *Number of Respondents:* 55; *Total Annual Responses:* 12; *Total Annual Hours:* 5,280.

To request copies of the proposed paperwork collection referenced above, E-mail your request, including your address, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Planning and Analysis Staff, Attention: Linda Mansfield, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: April 29, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–11384 Filed 5–7–96; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Receipt of Applications for Permit

The following applicants have applied for a permit to conduct certain activities with endangered species. This notice is provided pursuant to Section 10(c) of the Endangered Species Act of 1973, *as amended* (16 U.S.C. 1531, *et seq.*):

PRT–814546

Applicant: James Spotila, Drexel University, Philadelphia, PA

The applicant requests a permit to import blood and tissue samples from leatherback sea turtle (*Dermochelys coriacea*), green sea turtle (*Chelonia mydas agassizi*) and olive ridley sea turtle (*Lepidochelys olivacea*) from Costa Rica and India for the purpose of scientific research that will benefit the species in the wild. This notice covers activities conducted by the applicant over a five year period.

Written data or comments should be submitted to the Director, U.S. Fish and Wildlife Service, Office of Management Authority, 4401 North Fairfax Drive, Room 430, Arlington, Virginia 22203 and must be received by the Director within 30 days of the date of this publication.

Documents and other information submitted with these applications are available for review, *subject to the requirements of the Privacy Act and Freedom of Information Act,* by any party who submits a written request for a copy of such documents to the following office within 30 days of the date of publication of this notice: U.S. Fish and Wildlife Service, Office of Management Authority, 4401 North Fairfax Drive, Room 430, Arlington, Virginia 22203. Phone: (703/358–2104); FAX: (703/358–2281).

Dated: May 3, 1996.

Caroline Anderson,

Acting Chief Branch of Permits, Office of Management Authority.

[FR Doc. 96–11490 Filed 5–7–96; 8:45 am]

BILLING CODE 4310–55–P

Bureau of Land Management

[WO–300–1310–00]

Green River Basin Advisory Committee, Colorado and Wyoming

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of Meeting of the Green River Basin Advisory Committee.

SUMMARY: This notice sets forth the time schedule and agenda for the third meeting of the Green River Basin Advisory Committee (GRBAC).

DATES: Wednesday, May 22, 1996, from 8:00 a.m. until 7:00 p.m., and Thursday, May 23, 1996, from 8:00 a.m., until 4:00 p.m.

ADDRESSES: Moffat County Fairgrounds Pavilion, junction of Bellaire and 4th Street, Craig, CO 81625.

FOR FURTHER INFORMATION CONTACT: Terri Trevino, GRBAC Coordinator, Bureau of Land Management, P.O. Box 1828, Cheyenne, WY 82003, telephone (307) 775–6020; or Frank Salwerowicz, Bureau of Land Management, 2850 Youngfield St., Lakewood, CO 80215, telephone number (303) 239–3745.

SUPPLEMENTARY INFORMATION: The topics for the meeting will include:

1. Sub-group reports;
2. Dissemination of GRBAC information requests; and
3. Public comment.

This meeting is open to the public. Persons interested in making oral comments to the GRBAC or filing written statements for the GRBAC's consideration should notify the GRBAC Coordinator at the above address by May 14, 1996. Oral comments will be heard from 5:00 p.m., to 7:00 p.m., on Wednesday, May 22. The GRBAC may establish a time limit for oral statements.

Dated: April 29, 1996.

Mike Dombeck,

Acting Director, Bureau of Land Management.

[FR Doc. 96–11433 Filed 5–7–96; 8:45 am]

BILLING CODE 4310–84–M